Tenvir L

See also: Atripla

Tenvir L™ (Tenvir L disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.

Tenvir L combination is used together with other antiviral medicines to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Tenvir L does not cure or prevent HIV or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay the development of problems that usually result from AIDS or HIV disease. It will not keep you from spreading HIV to other people. People who receive Tenvir L may continue to have some of the problems usually related to AIDS or HIV disease.

Tenvir L is available only with your doctor's prescription.

Generic name: Lamivudine (Tenvir L) 300mg, Tenofovir (Tenvir L) DISOPROXIL FUMARATE 300mg

Dosage form: tablet, film coated

Medically reviewed on March 22, 2018.

Testing Prior to Initiation and During Treatment with Tenvir L

Prior to initiation of Tenvir L, test patients for hepatitis B virus infection.

It is recommended that serum creatinine, serum phosphorus, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating Tenvir L and during therapy in all patients as clinically appropriate.

Recommended Dosage for Adult and Pediatric Patients Weighing at Least 35 kg

Tenvir L is a two-drug fixed-dose combination product containing 300 mg of Lamivudine (Tenvir L) (3TC) and 300 mg of Tenofovir (Tenvir L) disoproxil fumarate (TDF). The recommended dosage of Tenvir L in HIV-1-infected adult and pediatric patients weighing at least 35 kg is one tablet taken orally once daily with or without food.

Not Recommended in Renal Impairment

Because Tenvir L is a fixed-dose combination tablet and cannot be dose adjusted, it is not recommended for patients with impaired renal function (creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Tenvir L (Lamivudine (Tenvir L) / Tenofovir (Tenvir L))

• Tenvir L Side Effects
• During Pregnancy
• Drug Interactions
• Support Group
• Pricing & Coupons
• En Español
• Drug class: antiviral combinations

Consumer resources

• Tenvir L
• Tenvir L (Advanced Reading)

Professional resources

• Tenvir L (FDA)

Related treatment guides

• HIV Infection

See also:
What is the most important information I should know about Tenvir L?

Tenvir L is contraindicated in patients with a previous hypersensitivity reaction to any of the components contained in the formulation.

Use: Labeled Indications

HIV-1 infection, treatment: Treatment of HIV-1 infection in combination with other antiretroviral agents in adult and pediatric patients weighing ≥35 kg.

See also:
What other drugs will affect Tenvir L?

Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir (Tenvir L) Products. Tenofovir (Tenvir L) Products may increase the serum concentration of Acyclovir-Valacyclovir. Monitor therapy

Adefovir: May diminish the therapeutic effect of Tenofovir (Tenvir L) Products. Adefovir may increase the serum concentration of Tenofovir (Tenvir L) Products. Tenofovir (Tenvir L) Products may increase the serum concentration of Adefovir. Avoid combination

Aminoglycosides: May increase the serum concentration of Tenofovir (Tenvir L) Products. Tenofovir (Tenvir L) Products may increase the serum concentration of Aminoglycosides. Monitor therapy

Atazanavir: Tenofovir (Tenvir L) Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Management: Must use boosted atazanavir in adults; give combo (atazanavir/ritonavir or atazanavir/cobicistat with Tenofovir (Tenvir L)) as a single daily dose with food. Pediatric patients, pregnant patients, and users of H2-blockers require other dose changes. Consider therapy modification

Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Monitor therapy

Cidofovir: May increase the serum concentration of Tenofovir (Tenvir L) Products. Tenofovir (Tenvir L) Products may increase the serum concentration of Cidofovir. Monitor therapy

Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. Avoid combination

Cobicistat: May enhance the adverse/toxic effect of Tenofovir (Tenvir L) Products. More specifically, cobicistat may impair proper Tenofovir (Tenvir L) monitoring and dosing. Monitor therapy

Darunavir: Tenofovir (Tenvir L) Disoproxil Fumarate may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Monitor therapy

Diclofenac (Systemic): May enhance the nephrotoxic effect of Tenofovir (Tenvir L) Products. Management: Seek alternatives to this combination whenever possible. Avoid use of Tenofovir (Tenvir L) with multiple NSAIDs or any NSAID given at a high dose. Consider therapy modification

Didanosine: Tenofovir (Tenvir L) Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenofovir (Tenvir L) Disoproxil Fumarate may increase the serum concentration of Didanosine. Management: Avoid use of Tenofovir (Tenvir L) disoproxil fumarate and didanosine when possible. If combined in adults with CrCL greater than 60 mL/min, decrease didanosine to 250 mg daily if 60 kg or more or to 200 mg if less than 60 kg. Avoid if CrCL is less than 60 mL/min. Consider therapy modification

Emtricitabine: Lamivudine (Tenvir L) may enhance the adverse/toxic effect of Emtricitabine. Avoid combination

Ganciclovir-Valganciclovir: Tenofovir (Tenvir L) Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir (Tenvir L) Products. Monitor therapy

Ledipasvir: May increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Management: Avoidance of this combination is recommended under some circumstances. Refer to full monograph for details. Consider therapy modification

Lopinavir: May enhance the nephrotoxic effect of Tenofovir (Tenvir L) Disoproxil Fumarate. Lopinavir may increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir (Tenvir L) Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of Tenofovir (Tenvir L) with multiple NSAIDs or any NSAID given at a high dose. Consider therapy modification

Orlistat: May decrease the serum concentration of Antiretroviral Agents. Monitor therapy

Simeprevir: Tenofovir (Tenvir L) Disoproxil Fumarate may decrease the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Monitor therapy

Sorbitol: May decrease the serum concentration of Lamivudine (Tenvir L). Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with Lamivudine (Tenvir L), but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased Lamivudine (Tenvir L) exposure. Consider therapy modification

Tipranavir: Tenofovir (Tenvir L) Disoproxil Fumarate may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Monitor therapy

Trimethoprim: May increase the serum concentration of Lamivudine (Tenvir L). Monitor therapy

Velpatasvir: May increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Monitor therapy

Voxilaprevir: Tenofovir (Tenvir L) Disoproxil Fumarate may increase the serum concentration of Voxilaprevir. Voxilaprevir may increase the serum concentration of Tenofovir (Tenvir L) Disoproxil Fumarate. Monitor therapy

See also:
What are the possible side effects of Tenvir L?

Applies to Lamivudine (Tenvir L) / Tenofovir (Tenvir L): oral tablet

Along with its needed effects, Tenvir L may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking Lamivudine (Tenvir L) / Tenofovir (Tenvir L):

More Common

• Fever
• pain
• stomach pain

Less Common

• Chest pain
• chills
• cough
• difficulty in moving
• joint pain or swelling
• muscle ache, cramp, pain, or stiffness
• sneezing
• sore throat
• tightness in the chest
• troubled breathing

Incidence Not Known

• Bloating
• bloody urine
• blurred vision
• bone fractures, especially of the femur
• bone pain
• cloudy urine
• constipation
• dark urine
• decreased appetite
• decreased frequency or amount of urine
• diarrhea
• difficulty swallowing
• dizziness
• dry mouth
• fast heartbeat
• fast, shallow breathing
• flushed, dry skin
• frequent urination
• fruit-like breath odor
• general feeling of discomfort
• hives, itching, skin rash
• increased blood pressure
• increased hunger
• increased thirst
• increased urination
• increased volume of pale, dilute urine
• indigestion
• irregular heartbeat
• large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
• light-colored stools
• loss of appetite
• lower back or side pain
• mood changes
• muscle weakness
• nausea
• numbness or tingling in the hands, feet, or lips
• pains in the stomach, side, or abdomen, possibly radiating to the back
• pale skin
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• seizures
• sleepiness
• stomach discomfort
• sweating
• swelling of the face, fingers, or lower legs
• troubled breathing with exertion
• unexplained weight loss
• unusual bleeding or bruising
• unusual tiredness or weakness
• upper right abdominal pain
• vomiting
• weight gain
• yellow eyes or skin

Some side effects of Lamivudine (Tenvir L) / Tenofovir (Tenvir L) may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

• Anxiety
• back pain
• belching
• burning, numbness, tingling, or painful sensations
• discouragement
• feeling sad or empty
• headache
• heartburn
• indigestion
• irritability
• lack or loss of strength
• loss of interest or pleasure
• redistribution or accumulation of body fat
• stomach upset
• tiredness
• trouble concentrating
• trouble sleeping
• unsteadiness or awkwardness
• weakness in the arms, hands, legs, or feet

Incidence Not Known

• Hair loss or thinning of hair